Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
COLORECTAL: Metastatic: 3rd Line: Post FOLFOX and FOLFIRI: LEAP 005-CRC

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Title
Merck MK-7902-005 LEAP-005-CRC
Study Title

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Site Link
Malignancy
Colon cancer, rectal cancer, colorectal cancer, CRC
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
3rd Line
Investigational Agent
Lenvatinib and Pembrolizumab
Drug Class
VEGF-R/FGFR inhibitor and PD-1 inhibitor
PI
Manjari Pandey, MD
Sponsor
Merck Sharp & Dohme Corp
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Colorectal cancer that has received 2 prior lines of therapy
  • Participants must have received 5-FU (or capecitabine), oxaliplatin and irinotecan (FOLFOX and FOLFIRI)
  • Adjuvant therapy is considered prior line only if progression within 6 months following completion
  • Not MSI-h or dMMR
  • No prior FOLFOXIRI or FOLFIRINOX
  • Measurable Disease per RECIST 1.1
  • Archival tissue or newly obtained tissue available
  • ECOG PS 0-1
  • BP < or = 150/90 at screening without change in antihypertensives within 1 week before C1D1
  • No evidence of malabsorption syndrome
  • No evidence of major blood vessel involvement
  • No clinically significant hemoptysis or tumor bleeding
  • No arterial thromboembolism within 12 months
  • No significant CAD within 12 months
  • No prior lenvatinib or checkpoint inhibitor therapy
  • Prior bevacizumab is allowed
  • No proteinuria defined as Uprotein >1g/24 hours
  • LVEF must be 55% or greater
  • No chronic systemic steroid or immunosuppressive therapy
  • No diagnosis of immunodeficiency
  • No active CNS metastases
  • No tumor involving the brain stem
  • No active autoimmune disease that has required treatment within last 2 years
  • No known HIV/HBV/HCV
Objective

Primary- ORR, safety Secondary- DCR, DoR, PFS, OS, PK

Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
Adenocarcinoma
Dosing Frequency
Control Agents
Study Protocol
Randomized
No
X